Latest Posts
-
CVS Won’t Add Gilead’s Yeztugo to Commercial Plans; FDA Rejection Spurs Krystal Trial Pause
CVS declines coverage for Gilead’s highly effective HIV prevention drug Yeztugo for now; an FDA rejection of a separate skin‑cancer therapy prompts Krystal to halt KB707 enrollment.
-
Epic’s AI Overhaul Leads a Week of Major Health Stories: Sarepta Fallout, Trans Data, Brain Study, and Statin Debate
Epic revealed new AI features for its dominant EHR as STAT covered developments from transgender population data to gene-therapy disappointments, a challenge to amputation brain theory, and shifting statin guidance.
-
Study Finds Somatosensory Body Map Largely Preserved After Hand Amputation
Longitudinal MRI of three patients shows brain maps for hand and lips remain stable after limb loss, challenging long-held reorganization theories.
-
VA’s Psychedelic Turn: MDMA Trials, Bipartisan Support, and a Push to Expand Veteran Access
After decades of underinvestment, the VA has begun funding psychedelic research — but Congress must sustain funding, training, and pilot programs to bring FDA‑approved therapies to veterans.
-
When Survival Isn’t Enough: Recognizing the Hidden Trauma of Illness
Medical trauma — the emotional disconnection that follows serious illness — is common but routinely overlooked in health care.
-
CDC Shooter Likely Scoped Atlanta Campus Days Before Deadly Attack, Internal Email Shows
Security footage suggests Patrick Joseph White attempted to enter the CDC’s Atlanta visitor center days before the shooting that killed a police officer, prompting stepped-up protections and staff calls to curb anti-public-health rhetoric.
-
Epic unveils Microsoft-powered AI scribe and assistants as EHR AI race heats up
Epic CEO Judy Faulkner announced Microsoft-powered AI tools and assistants to tackle clinician documentation and patient questions.
-
Recalibrating Risk: PREVENT Model Suggests Lower Statin Threshold Keeps Eligibility Stable
A revised risk calculator (PREVENT) lowers estimated cardiovascular risk, and adopting a 3% 10-year threshold would keep statin eligibility similar to current levels.
-
AI scribes, GLP‑1 drugs and mosquito outbreaks: five forces pushing health spending higher
AI-enhanced billing, rising drug and mental‑health costs, expanding mosquito-borne disease, federal limits on gender‑affirming care, and calls for price transparency are reshaping health spending and coverage.